Breast Cancer
From the Journals
PAM50-based score identifies low-risk subset with node-positive early-stage breast cancer
About 37% of patients with a single positive lymph node and 15% of patients with two positive nodes were identified as low risk, with very...
From the Journals
AHA: Heart health helps optimize breast cancer outcomes
Cardiovascular health should be monitored at every step, from breast cancer diagnosis to after treatment.
From the Journals
Hodgkin lymphoma survivors are at an increased risk of subsequent ER-negative breast cancer
Subsequent risk of estrogen receptor–negative breast cancer was elevated irrespective of the type of therapy given for Hodgkin lymphoma.
Conference Coverage
Pembrolizumab plus SBRT shows promise for advanced solid tumors
Pembrolizumab immunotherapy with multi-site SBRT appears to be a safe and effective treatment in patients with advanced solid tumors.
From the Journals
STUDY: More mammograms after cost-sharing elimination
The elimination of cost sharing for mammograms under the ACA was associated with increased rates of using the service among older women, according...
From the Journals
New multi-analyte blood test shows promise in screening for several common solid tumors
Newly developed CancerSEEK utilizes combined assays for genetic alterations and protein biomarkers and has the capacity to identify the presence...
From the Journals
POSH study: BRCA mutations did not influence survival in young onset breast cancer
BRCA-positive and BRCA-negative women had similar overall survival at 2 years, 5 years, and 10 years after diagnosis.
News
FDA approves PARP inhibitor for BRCA+ advanced breast cancer
This is the first FDA approval of a PARP inhibitor to treat breast cancer and the first approval for treatment of patients with metastatic breast...
From the Journals
Pain after breast surgery may not be caused by the operation
The source of postop pain in breast surgery patients is not well understood.
From the Journals
Modeling study: Screening, treatment effects on breast cancer mortality vary by subtype
Breast cancer mortality reductions over time are associated with treatment and screening advances but vary by molecular subtype of disease.
Conference Coverage
Trial updates will help tailor endocrine therapy for premenopausal breast cancer
SAN ANTONIO – In an updated joint analysis of TEXT and SOFT, benefit of AI plus OFS over tamoxifen plus OFS was sustained, with a 4.0% absolute...